Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

;All manufacturing costs for KRYSTEXXA after FDA approval are recorded as inventory as opposed to research and development prior to approval.

Selling, general and administrative expenses increased $15.0 million to $22.3 million for the three months ended September 30, 2011, from $7.3 million for the three months ended September 30, 2010.  The higher expenses for the three months ended September 30, 2011 were primarily due to increased selling and marketing expenses associated with the full commercial launch of KRYSTEXXA.  

Interest expense on the Company's convertible notes was $3.4 million for the three months ended September 30, 2011.

Conference Call and WebcastThe Company will host a live conference call and webcast beginning at 9:00 a.m. Eastern Time on November 3, 2011 to discuss these results and to answer questions.  To participate by telephone, please dial:Domestic:

866-393-9370 International:

706-679-1207 Conference ID:

17722127The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary. A telephone replay will be available from 12:00 p.m. Eastern Time on November 3, 2011 through 12:00 a.m. Eastern Time on November 17, 2011 by dialing:Domestic:

855-859-2056 or 800-585-8367 International:

404-537-3406 Conference ID:

17722127ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Moun
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
2. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
3. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
4. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
5. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
6. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
7. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
8. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
9. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
10. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
11. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation ... its CytoSorb® blood purification technology to help fight ... in 28 countries worldwide, today announced the appointment ... MD, FACS, as its Senior Vice President of ... Dr. Di Russo is an ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Depomed, Inc. (NASDAQ: DEPO ) today ... payment from Ironwood Pharmaceuticals, Inc. following the development and ... candidate meeting pre-specified attributes under its Research Collaboration and ... in July 2011. Under the terms of the agreement, Depomed ...
... China, May 11, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... a leading pharmaceutical company specializing in the development, manufacturing, ... today announced that the annual general meeting of shareholders ... 2012 at 10 a.m. Beijing time. The meeting will ...
Cached Medicine Technology:Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc. 2Simcere Pharmaceutical Group Provides Notice of Annual General Meeting 2
(Date:12/26/2014)... India Network Foundation, a non-profit US based sponsor ... a new version of “ EasySelect ”, a software ... for their visiting parents. The technology tool is designed ... when choosing an insurance plan by showing the benefits ... clicks. Many elderly Asian Indian parents often find it ...
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast and ... landscape, unmet needs, current pipeline and commercial opportunities in ... which is typically used for treating colorectal cancer. It ... gastric cancer and pancreatic cancer. TS-1 is composed of ... approved in 1999 in Japan for the treatment of ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... 41, were well aware of the toll that morbid ... from high blood pressure, diabetes and thyroid disease and ... they scheduled their gastric bypass surgeries at Cedars-Sinai Medical ... joined a growing number of severely overweight Americans who ...
... been the cornerstones of managing type 2 diabetes. But ... ,Now, a new systematic review shows that exercise ... sensitivity to insulin, and decreases blood lipids (fats) while ... 2 diabetes is an increasing problem in Western societies ...
... anti-smoking group, has admitted to making use of an actor ... cancer//. ,The advertisement shows a heavily made-up woman displaying ... and nose, who warns that smoking caused her mouth cancer. ... she says. ,Todd Harper, Quit executive director, said ...
... rare form of viral fever, has taken the form of ... reportedly infected with its virus in eight states, an official ... magnitude. There is no case of Chikungunya reported from the ... Kerala in the southern India, other states like Tamil Nadu, ...
... potential drugs that interfere with the action of one ... problems led scientists// at Johns Hopkins to create a ... to see multiple, real-time chemical reactions in living cells. ... in the journal ACS Chemical Biology. ,Most ...
... Burgess Hill, West Sussex was prosecuted for intentionally infecting his ... to arrest him.// ,He failed to appear ... Court that the 47-year-old businessman would be sentence in his ... bodily harm to his lover. James has admitted infecting his ...
Cached Medicine News:Health News:Weight-Loss Surgeries Changing Lives 2Health News:Weight-Loss Surgeries Changing Lives 3Health News:Weight-Loss Surgeries Changing Lives 4Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 2Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 3Health News:New Tool to Watch Real-Time Chemical Activity in Cells 2Health News:New Tool to Watch Real-Time Chemical Activity in Cells 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: